drugset / Trial / NCT02715479

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

NCT02715479

Phase 1 Completed 14 enrolled ViiV Healthcare GlaxoSmithKline · collab
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to evaluate how BMS955176 affects pharmacokinetics (PK) of Dolutegravir (DTG) and also how DTG administration affects the PK of BMS955176

Timeline

Start
2016-04
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-955176 Other / unclassified
Subject Dolutegravir Other / unclassified